Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06974110 · ClinicalTrials.gov registry record · Phase 1

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

A Phase 1 study of Colorectal Cancer and Advanced Solid Tumor, sponsored by MOMA Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
132
Enrollment target
13
Study locations

NCT06974110 is a Phase 1 study of Colorectal Cancer and Advanced Solid Tumor that is actively recruiting participants, run by MOMA Therapeutics. The registered enrollment target is 132 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The trial reports 13 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06974110, a Phase 1 study of Colorectal Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by MOMA Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
132 participants
Enrollment target
13
Study locations

Study Summary

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.

Conditions Studied

Colorectal Cancer Advanced Solid Tumor Endometrial Cancer Gastric Cancer Metastatic Solid Tumor MSI-H Cancer dMMR Cancer

Interventions

  • DRUG Irinotecan
  • DRUG Immunotherapy
  • DRUG MOMA-341

Study Locations (13)

Texas

  • Investigative Site #127 - Dallas
  • Investigative Site #129 - Houston

New South Wales

  • Investigative Site #122 - Sydney
  • Investigative Site #123 - Westmead

Florida

  • Investigative Site #128 - Tampa

Michigan

  • Investigative Site #120 - Detroit

Missouri

  • Investigative Site #110 - St Louis

North Carolina

  • Investigative Site #131 - Raleigh

Oregon

  • Investigative Site #121 - Portland

Queensland

  • Investigative Site #124 - Woolloongabba

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2025-07-16
Est. Completion 2028-05
Phase Phase 1

Sponsor

MOMA Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06974110

The ClinicalTrials.gov registry entry for NCT06974110 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The listed sponsor is MOMA Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Irinotecan is the first listed.

NCT06974110 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Texas, New South Wales, Florida.

Frequently Asked Questions

What is clinical trial NCT06974110 about?

NCT06974110 is a clinical study titled "Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors". This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients wi...

What is the current status of trial NCT06974110?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2025-07-16. Estimated completion is 2028-05.

What conditions does trial NCT06974110 study?

This clinical trial studies the following conditions: Colorectal Cancer, Advanced Solid Tumor, Endometrial Cancer, Gastric Cancer, Metastatic Solid Tumor.

What interventions are being tested in trial NCT06974110?

The interventions under investigation include: Irinotecan (DRUG), Immunotherapy (DRUG), MOMA-341 (DRUG).

Who is sponsoring clinical trial NCT06974110?

This trial is sponsored by MOMA Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06974110 being conducted?

This trial has 13 study locations across Florida, Michigan, Missouri, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Advanced Solid Tumor

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.